Synthesis, binding properties and receptor docking of 4-halo-6-[2-(4-arylpiperazin-1-yl)ethyl]-1H-benzimidazoles, mixed ligands of D2 and 5-HT1A receptors

European Journal of Medicinal Chemistry

Volumn 43, Issue 8, 2008, Pages 1696-1705

  Andrić, Deana ^a   Roglić, Goran ^a   Šukalović, Vladimir ^b   Šoškić, Vukić ^c   Kostić Rajačić, Sladjana ^b  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b Institute for Chemistry   (Serbia)

^c PROTEOSYS AG   (Germany)

Author keywords

Dopamine receptor; Rational drug design; Serotonin receptor

Indexed keywords

4 BROMO 6 [2 (4 PHENYLPIPERAZIN 1 YL)ETHYL] 1H BENZIMIDAZOLE; 4 BROMO 6 [2 [4 (2 CHLOROPHENYL)PIPERAZIN 1 YL]ETHYL] 1H BENZIMIDAZOLE; 4 BROMO 6 [2 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]ETHYL] 1H BENZIMIDAZOLE; 4 BROMO 6 [2 [4 (2 PYRIMIDINYL)PIPERAZIN 1 YL]ETHYL] 1H BENZIMIDAZOLE; 4 BROMO 6 [2 [4 [3 (TRIFLUOROMETHYL)PHENYL]PIPERAZIN 1 YL]ETHYL] 1H BENZIMIDAZOLE; 4 CHLORO 6 [2 (4 PHENYLPIPERAZIN 1 YL)ETHYL] 1H BENZIMIDAZOLE; 4 CHLORO 6 [2 [4 (2 CHLOROPHENYL)PIPERAZIN 1 YL]ETHYL] 1H BENZIMIDAZOLE; 4 CHLORO 6 [2 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]ETHYL] 1H BENZIMIDAZOLE; 4 CHLORO 6 [2 [4 (2 PYRIMIDINYL)PIPERAZIN 1 YL]ETHYL] 1H BENZIMIDAZOLE; 4 CHLORO 6 [2 [4 [3 (TRIFLUOROMETHYL)PHENYL]PIPERAZIN 1 YL]ETHYL] 1H BENZIMIDAZOLE; BENZIMIDAZOLE DERIVATIVE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; HALOGEN; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG;

AB INITIO CALCULATION; ARTICLE; BINDING AFFINITY; DRUG BINDING; DRUG SYNTHESIS; ENERGY; RADIOASSAY;

BENZIMIDAZOLES; COMPUTER SIMULATION; HALOGENS; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PIPERAZINES; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN, 5-HT1;

EID: 48049117780     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2007.09.027     Document Type: Article

References (30)

1. Zhang A., Neumeyer J.L., and Baldessarini R.J. Chem. Rev. 107 (2007) 274-302
2. Stahl M.S. J. Clin. Psychiatry 5 (2003) 9-13
3. Farah A. J. Clin. Psychiatry 7 (2005) 268-274
4. Conley R.R., and Kelly D.L. Curr. Drug Targets CNS Neurol. Disord. 1 (2002) 123-128
5. Tamminga C.A., and Carlsson A. Curr. Drug Targets CNS Neurol. Disord. 1 (2002) 141-147
6. Bruins S.L.A., Kleven M.S., and Newman-Tancredi A. Neuropharmacology 49 (2005) 996-1006
7. Assie M.B., Ravailhe V., Faucillon V., and Newman-Tancredi A. J. Pharmacol. Exp. Ther. 315 (2005) 265-272
8. Cuisiat S., Bourdiol N., Lacharme V., Newman-Tancredi A., Colpaert F., and Vacher B. J. Med. Chem. 50 (2007) 865-876
9. Šoškić V., and Joksimović J. Curr. Med. Chem. 5 (1998) 493-512
10. Šukalović V., Andrić D., Roglić G., Kostić-Rajačić S., and Šoškić V. Arch. Pham. Pharm. Med. Chem. 337 (2004) 376-382
11. Metrangolo P., Neukirch H., Pilati T., and Resnati G. Acc. Chem. Res. 38 (2005) 386-395
12. Auffinger P., Hays F.A., Westhof E., and Ho P.S. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 16789-16794
13. Politzer P., Lane P., Concha M.C., Ma Y., and Murray J.S. J. Mol. Model. 13 (2007) 305-311
14. Teeter M.M., Froimowitz M., Stec J.B., and DuRand C.J. J. Med. Chem. 37 (1994) 2874-2888
15. Šukalović V., Zlatović M., Andrić D., Roglić G., Kostić-Rajačić S., and Šoškić V. Arch. Pham. Pharm. Med. Chem. 337 (2004) 502-512
16. Zlatović M.V., Šukalović V.V., Schneider C., and Roglić G.M. Bioorg. Med. Chem. 14 (2006) 2994-3001
17. Lan H., Durand C.J., Teeter M.M., and Neve K.A. Mol. Pharmacol. 69 (2006) 185-194
18. Wilcox R.E., Huang W.H., Brusniak M.Y., Wilcox D.M., Pearlman R.S., Teeter M.M., DuRand C.J., Wiens B.L., and Neve K.A. J. Med. Chem. 43 (2000) 3005-3019
19. Neve K.A., Cumbay M.G., Thompson K.R., Yang R., Buck D.C., Watts V.J., DuRand C.J., and Teeter M.M. Mol. Pharmacol. 60 (2001) 373-381
20. Ballesteros J.A., Shi L., and Javitch J.A. Mol. Pharmacol 60 (2001) 1-19
21. Sali A., and Blundell T.L. J. Mol. Biol. 234 (1993) 779-815
22. Shi L., and Javitch J.A. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 440-445
23. Bondensgaard K., Ankersen M., Thøgersen H., Hansen B.S., Wulff B.S., and Bywater R.P. J. Med. Chem. 47 (2004) 888-899
24. SGI Octane2 is trademark of Silicon Graphics, Inc, CA, USA ().
25. PovRay, Persistence of Vision Raytrace is trademark of PovRay team, ().
26. Frisch M.J., Trucks G.W., Schlegel H.B., Scuseria G.E., Robb M.A., Cheeseman J.R., Montgomery Jr. J.A., Vreven T., Kudin K.N., Burant J.C., Millam J.M., Iyengar S.S., Tomasi J., Barone V., Mennucci B., Cossi M., Scalmani G., Rega N., Petersson G.A., Nakatsuji H., Hada M., Ehara M., Toyota K., Fukuda R., Hasegawa J., Ishida M., Nakajima T., Honda Y., Kitao O., Nakai H., Klene M., Li X., Knox J.E., Hratchian H.P., Cross J.B., Bakken V., Adamo C., Jaramillo J., Gomperts R., Stratmann R.E., Yazyev O., Austin A.J., Cammi R., Pomelli C., Ochterski J.W., Ayala P.Y., Morokuma K., Voth G.A., Salvador P., Dannenberg J.J., Zakrzewski V.G., Dapprich S., Daniels A.D., Strain M.C., Farkas O., Malick D.K., Rabuck A.D., Raghavachari K., Foresman J.B., Ortiz J.V., Cui Q., Baboul A.G., Clifford S., Cioslowski J., Stefanov B.B., Liu G., Liashenko A., Piskorz P., Komaromi I., Martin R.L., Fox D.J., Keith T., Al-Laham M.A., Peng C.Y., Nanayakkara A., Challacombe M., Gill P.M.W., Johnson B., Chen W., Wong M.W., Gonzalez C., and Pople J.A. Gaussian 03, Revision C.02 (2004), Gaussian Inc., Wallingford CT
27. Boys S.F., and Bernardi F. Mol. Phys. 19 (1970) 553-566
28. Tuce Z., Šoškić V., and Joksimović J. Drug Des. Discov. 11 (1994) 251-258
29. Dukić S., Kostić-Rajačić S., Dragović D., Šoškić V., and Joksimović J. J. Pharm. Pharmacol. 49 (1997) 1036-1041
30. GraphPad Prism is a biostatistical and curve fitting software packet by GraphPad Software ().